Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MARIO: IV echinocandin followed by oral ibrexafungerp vs IV echinocandin followed by oral fluconazole for candidemia/invasive candidiasis
2024-511755-18-00Phase 3Completed
- Sponsor
- SCYNEXIS, Inc.
- Start
- Jun 2024
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial of ibrexafungerp in candidemia and invasive candidiasis (2 arms), sponsored by SCYNEXIS, Inc. Primary endpoints: All-cause mortality at Day 30 and Successful Global Response at end of therapy (EOT). Started Jun 2024; status: completed.
02
Drugs
ibrexafungerp
03
Conditions
candidemiainvasive candidiasis
Beyond the preview
Go deeper on 2024-511755-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511755-18-00.